Contineum Therapeutics
CTNM15.4901.65% ( -0.260 )
Contineum Therapeutics (CTNM)
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflamm...
- Open
- 15.750
- High
- 16.080
- Low
- 14.125
- Prev. Close
- 15.750
- Volume
- 449.58K
- Turnover
- 6.74M
- Avg Price
- 14.984
- Bid/Ask Ratio
- --
- Amplitude
- 12.41%
- 52wk High
- 16.910
- Volume Ratio
- 2.77
- Turnover Ratio
- 1.63%
Contineum Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 31, 2026Price forecast
$22.8647.56%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy12.50%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 17 hours ago
Contineum Therapeutics (NASDAQ:CTNM) Announces Quarterly Earnings Results
- Tip Ranks · 22 hours ago
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
- Earnings Watch · 1 day ago, 03:19 PM
Contineum Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- TradingView · Jul 13 at 03:23 PM
Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029
- PUBT · Jul 10 at 04:21 PM
Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 16,640 in common shares
- PUBT · Jul 8 at 05:49 PM
Contineum Therapeutics CEO Carmine N. Stengone disposes of 2,500 shares for $40,000
